Study R-FACT Risk factors for alloimmunization against red blood cell transfusions: a case cohort study

Study R-FACT Risk factors for alloimmunization against red blood cell transfusions: a case cohort study - R-FACT Risk Factors for Alloimmunisation by red blood Cell Transfusions

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44808

Enrollment

1500

Registered

2010-02-02

Start date

2010-09-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

red blood cell immunization transfusion related hemolysis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patients for the first time diagnosed with transfusion dependent red blood cell alloantibodies (=patients who received transfusions before detection of alloantibodies). - Patients who have been transfused, yet did not form red cell alloantibodies afterwards

Exclusion criteria

Exclusion criteria: - Age below 18 years - Patients with transfusions prior to the start of study inclusion period.

Design outcomes

Primary

Measure	Time frame
Our case-control study will quantify and characterize clinical risk factors of patients and conditions for transfusion associated alloimmunisation. Patients will be given a questionnaire to assess environmental and life style risk factors. Blood sampling (upon informed consent) and buccal mucosal swabs will be carried out to determine genetic variation of immunization against red blood cell antigens.	—

Measure

Time frame

Our case-control study will quantify and characterize clinical risk factors of patients and conditions for transfusion associated alloimmunisation. Patients will be given a questionnaire to assess environmental and life style risk factors. Blood sampling (upon informed consent) and buccal mucosal swabs will be carried out to determine genetic variation of immunization against red blood cell antigens.

—

Secondary

Measure	Time frame
-na-	—

Countries

Netherlands

Outcome results